The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Insights into the DREAMM-14 trial
Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly discusses the DREAMM-14 trial (NCT05064358), which is evaluating different dosing regimens of belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM), with the main aim of minimizing the ocular toxicity associated with this agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research Funding: GSK, Amgen, Daiichi Sankyo, Cosette
Advisory board: BMS
Consultancy: Curio Science LLC, Intellisphere LLC
Membership on an entity’s Board of Directors or advisory committees: GSK
